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Abstract: Pregnancy-related disorders, including preeclampsia and gestational diabetes, are
characterized by the presence of an adverse intrauterine milieu that may ultimately result in
oxidative and nitrosative stress. This scenario may trigger uncontrolled production of reactive oxygen
species (ROS) such as superoxide anion (O•−) and reactive nitrogen species (RNS) such as nitric oxide
(NO), along with an inactivation of antioxidant systems, which are associated with the occurrence of
relevant changes in placental function through recognized redox post-translational modifications in
key proteins. The general objective of this study was to assess the impact of a maternal obesogenic
enviroment on the regulation of the placental nitroso-redox balance at the end of pregnancy. We
measured oxidative damage markers—thiobarbituric acid-reacting substances (TBARS) and carbonyl
groups (C=O) levels; nitrosative stress markers—inducible nitric oxide synthase, nitrosothiol groups,
and nitrotyrosine residues levels; and the antioxidant biomarkers—catalase and superoxide dismutase
(SOD) activity and expression, and total antioxidant capacity (TAC), in full-term placental villous from
both pre-pregnancy normal weight and obese women, and with absence of metabolic complications
throughout gestation. The results showed a decrease in C=O and TBARS levels in obese pregnancies.
Although total SOD and catalase concentrations were shown to be increased, both activities were
significantly downregulated in obese pregnancies, along with total antioxidant capacity. Inducible
nitric oxide sintase levels were increased in the obese group compared to the lean group, accompanied
by an increase in nitrotyrosine residues levels and lower levels of nitrosothiol groups in proteins
such as ERK1/2. These findings reveal a reduction in oxidative damage, accompanied by a decline
in antioxidant response, and an increase via NO-mediated nitrative stress in placental tissue from
metabolically healthy pregnancies with obesity. All this plausibly points to a placental adaptation
of the affected antioxidant response towards a NO-induced alternative pathway, through changes
in the ROS/RNS balance, in order to reduce oxidative damage and preserve placental function
in pregnancy.
Antioxidants 2020, 9, 794; doi:10.3390/antiox9090794 www.mdpi.com/journal/antioxidants
Antioxidants 2020, 9, 794 2 of 17
Keywords: oxidative stress; nitrosative stress; placenta; obesity; antioxidant; nitration;
pregnancy-related disorder
1. Introduction
Obesity is considered a chronic low-grade inflammation with multifactorial etiology and has
become a serious public health problem because of its increasing prevalence in low-income countries,
especially among middle-aged women [1]. The incidence of obesity is of particular concern among
women at reproductive age because of its impact during pregnancy. Maternal obesity is closely related
to some obstetric complications and poor pregnancy outcomes, including preeclampsia (PE), gestational
diabetes mellitus (GDM), preterm birth, or cesarean delivery, which increase an overall risk of severe
morbidity or mortality in the maternal–fetal unit [2–6]. In addition, excessive adiposity or weight gain
in pregnancy may have a significantly impact over the intrauterine environment and, consequently,
on fetal development and the child’s health later in life by fetal metabolic programming that could
ultimately promote an increased risk of developing metabolic syndrome, diabetes, or cardiovascular
disease [7–9].
Obesity in pregnancy is characterized by the presence of hyperlipidemia and heightened
inflammatory state, including higher levels of pro-inflammatory mediators [10,11]. This adverse
environment can eventually lead to changes in placental function and, subsequently, complications in
fetal development [12–14]. The placenta per se is an important source of production of pro-oxidant
agents in normal pregnancy, mainly due to the presence of a high mitochondrial metabolic activity and
the action of enzymes such as NADPH oxidase or xanthine oxidase, responsible for the production of
reactive oxygen species (ROS) such as superoxide anion (O2•−) or hydrogen peroxide (H2O2). Under
normal physiological conditions, these reactive species play important roles as second messengers in
the cell signaling regulation. In pregnancy, these pathways can respond to a variety of stimuli or insult
related to perturbations in the maternal blood supply to the placenta and inflammation.
On the other hand, the placenta has a complex system of antioxidant response, including
superoxide dismutase (SOD) or catalase (CAT) enzymes, which usually maintains the action of ROS in
balance [15,16]. When the production of ROS exceeds the endogenous antioxidant defenses, a process
known as oxidative stress (OS) occurs. OS is now recognized to play an essential role in certain
placental-related disorders in pregnancy such as GDM, PE, and intrauterine growth retardation [17–20].
Nevertheless, the impact of an obesogenic milieu on placental redox status is still not completely
understood. In this line, the maternal obesity associated with metabolic alterations seems to lead to
the appearance of an elevated placental OS compromising both placental metabolism and antioxidant
status. In contrast, no clear evidence has been found of increased OS in human placenta associated
with increasing maternal body mass index (BMI), especially in overweight pregnant women [21,22].
Interestingly, pregravid maternal obesity contributes to the development of placental oxidative stress
already in the first trimester of pregnancy [23].
In addition to ROS, the placenta can also generate reactive nitrogen species (RNS) in response
to different inflammatory and metabolic mediators. Among them, nitric oxide (NO) is a pleiotropic
signaling agent able to regulate key biological processes at the cellular level. An overproduction
of NO by the nitric oxide synthase (NOS) enzyme has been widely implicated in the pathogenesis
of different disorders, including cancer, diabetes, autoimmune, and cardiovascular diseases, along
with pregnancy-related pathologies [24]. In these events, NO disrupts protein signaling pathways
by mechanisms termed post-translational modifications (PTMs), including protein S-Nitrosylation
and Nitration, which may affect its biological functions by forming NO-derived complexes known as
S-nitrosothiol (−SNO) and nitrotyrosine (−NO2), respectively. Our group has recently pointed out
S-Nitrosylation as a crucial mechanism through which NO specifically regulates certain key placental
proteins in pregnancies with GDM [25]. This phenomenon has also been proposed to play a role in
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the placental pathophysiology in PE, both leading to nitrosative stress [26]. Moreover, the combination
of NO and O2•− produces peroxynitrites (ONOO•−), a powerful pro-oxidant that can exert different
deleterious effects by protein nitration, forming nitrotyrosine residues [27]. In this line, many relevants
cellular proteins are potential ONOO•− targets, including transporters, enzymes, structural proteins,
and signal transduction molecules, affecting protein formation and eventually placental function, and
fetal growth and development. This process has been previously identified in the placenta from PE
and GDM pregnancies in association with an altered placental function [28,29].
All this seems to indicate that both ROS and RNS are highly present in human placenta under
pathological conditions related to pregnancy, causing harmful effects on cellular proteins and leading
to loss of function. Unlike other pathological states associated with pregnancy, little attention has been
dedicated to the role of placental oxidative and nitrosative stress in cases of pregnancies with maternal
obesity, particularly in those with a lack of metabolic complications during the course of pregnancy. In
this sense, the overall goal of this study was to evaluate the effects of a metabolically healthy pregnancy
with pregravid obesity in the balance of ROS/RNS/antioxidants system in full-term placentas.
2. Material and Methods
This study was previously approved by the Ethics Committee of Hospital Universitario “Puerta
del Mar” (Cádiz, Spain) with study identification code 04.2012, in accordance with the protocols
established in the Declaration of Helsinki. All participants in this study were previously informed and
gave their written consent in order to be included as study subjects.
2.1. Products and Antibodies
All the chemical products used in this work were purchased from Sigma (St. Louis, MO, USA),
Biorad (Hercules, CA, USA), and Thermo Scientific (Madrid, Spain). Primary (anti-ERK1/2, anti-SOD
1, anti-catalase, and β-actin) and secondary antibodies came from Cell Signaling Technology (Danvers,
MA, USA). iNOS antibody was from R&D Systems (Minneapolis, MN, USA) and nitrotyrosine antibody
was from Merck Millipore (Darmstadt, Germany).
2.2. Study Subjects
The study groups consisted of nine normal weight (Lean; pre-pregnancy BMI < 25 kg/m2) and
eight obese (OB; pre-pregnancy BMI ≥ 30 kg/m2) pregnant women who gave birth at the Obstetric
and Gynecology unit of University Hospital “Puerta del Mar” (HUPM). All patients included in
the study had no history of PE, hypertension disorders, chronic diseases, fetal anomalies, smoking
habits, infections, or metabolic complications. Furthermore, the participants were classified with
metabolically healthy phenotype (uncomplicated pregnancy) mainly following three criteria proposed
by Rey-López et al.: high-density lipoprotein cholesterol, triglycerides, and plasma glucose [30]. BMI
≥ 30 kg/m2 was the main indicator used to define maternal obesity. All participants showed a normal
glucose tolerance at 24–28 weeks following the criteria and protocols established by the National
Diabetes Data Group [31]. The indications for elective caesarean section at term were breech presentation
and previous caesarean section.
2.3. Tissue Collection and Placental Samples
All placentas included in the study were quickly collected after a scheduled cesarean section in
the Obstetrics and Gynecology unit of University Hospital “Puerta del Mar”. Placentas were placed on
ice and transported to the research laboratory within 10 min of delivery. Then, decidual tissue and
large vessels were removed from villous placenta by blunt dissection on aseptic culture conditions.
Afterward, small fragments of villous (~100 mg) were isolated from the central area of the placenta,
close to the umbilical cord, washed in cold PBS to remove attached blood, and stored at −80 ◦C until
further analysis.
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2.4. Protein Extract Preparation
Total proteins were extracted from frozen placental samples following homogenization in lysis
buffer in combination with protease inhibitors and phenylmethylsufonyl fluoride (PMSF). After 30 min
on ice, extracts were sonicated and centrifugated at 18,000× g for 5 min at 4 ◦C. Then, pellets were
removed and supernatants (protein extracts) were used for further analysis. Total proteins were
quantified by the bicinchoninic acid method (Thermo Scientific, Madrid, Spain).
2.5. Measurement of Total Protein Expression by SDS-Western Blotting Assay
Equal concentrations of solubilized proteins (40 µg/sample) were denatured by heat at 100 ◦C
for 5 min in sodium dodecyl sulfate (SDS) sample buffer, resolved by 6–12% SDS-polyacrylamide gel
electrophoresis (SDS-PAGE), transferred to polyvinylidenedifluorid (PVDF) membranes and blotted
with primary antibodies directed against the different proteins of study (Catalase, SOD, nitrotirosine,
and iNOS) at a dilution of 1:500–1:1000, and secondary antibodies used at a dilution of 1:5000.
The incubated membranes were visualized by the chemiluminiescence method using WesternBright
Sirius Horseradish Peroxidase (HRP) substrate (Advansta Inc., San Jose, CA, USA). Band intensity
for each protein was quantified by the Image-J program (Wisconsin, NIH, USA). The membrane was
stripped and re-tested with β-actin as a protein loading control for each of the proteins examined.
2.6. Determination of Oxidative Status Markers
2.6.1. Lipid Peroxidation (LPO)
Thiobarbituric acid-reacting substances (TBARS) were measured by the spectrophotometric
method described by Buege et al. [32]. The values were expressed as nmol of malondialdehyde
(MDA)/mg protein in placental tissue.
2.6.2. Carbonyl Groups (C=O)
For the determination of carbonyl groups in placental tissue, the spectrophotometric dinitrophenyl
hydrazine method of Levine et al. was followed for every sample, with a blank for each one [33].
Samples containing at least 0.5 mg extract protein were incubated with 0.3% (v/v) Triton X-100 and 1%
(w/v) streptomycin sulphate for 20 min to remove the nucleic acids and were centrifuged at 2000× g.
Supernatants (200 µL) were mixed with 300 µL of 10 mM 2,4-dinitrophenylhydrazine (DNPH) in 2 M
HCl. The blank was incubated in 2 M HCl. After 1 h of incubation at room temperature, proteins were
precipitated with 10% (w/v) trichloroacetic acid and the pellets were washed three times with 500 µL of
ethanol:ethylacetate (1:1). The pellets were finally dissolved in 6 M guanidine hydrochloride in 20 mM
potassium phosphate at pH 2.3, and the absorption at 370 nm was measured. Protein recovery was
estimated for each sample by measuring at 280 nm. Carbonyl content was calculated using a molar
absorption coefficient for aliphatic hydrazones of 22,000 M−1 cm−1.
2.7. Determination of Antioxidant Defense Markers
2.7.1. Native SDS-PAGE SOD Activity
Total SOD activity in the placental homogenates was evaluated by analysis of the isoenzymatic
SOD pattern. Sample proteins were separated by native polyacrylamide gel electrophoresis (PAGE) on
10% acrylamide gels, and isoenzymes were visualized in gels by nitro blue tetrazolium (NBT) staining.
SOD isozymes were detected in gels as achromatic bands over a blue background, a consequence of
the NBT reduction to formazan blue by the O2•− radicals generated in the assay [34].
2.7.2. Catalase Activity
Catalase activity was determinated by spectrophotometric analysis of hydrogen peroxide
breakdown at 240 nm, as described by the method of Aebi [35].
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2.7.3. Total Antioxidant Capacity
Total antioxidant capacity (TAC) assay was measured by the method described by Erel [36].
Results were expressed as µmol of trolox equivalents per mg of proteins in placental tissue.
2.8. Nitrosative Stress Markers
2.8.1. S-Nitrosylated Protein Detection by Biotin Switch Assay
S-nitrosylated proteins were detected using the Biotin-Switch assay described by Jaffrey and
Snyder with a few minor modifications [37]. Placental samples (~50 mg) were homogenized in lysis
buffer (100 mM Hepes-NaOH, 1 mM EDTA, 0.5 mM PMSF, 1% Triton X-100, 0.1% SDS, and 0.1 mM
neocuproine, pH 7.2). Equal amounts of proteins in each lane were determined using the BCA protein
kit. 1 mg protein was mixed with 400 µL blocking buffer (25% SDS, 10 mM MMTS in standard buffer,
containing 100 mM Hepes-NaOH, 1 mM EDTA, and 0.1 mM neocuproine, pH 7.2) and boiled in
agitation at 55 ◦C in the dark for 30 min in order to allow S-methylthiolation of each cysteine thiol
using S-methylmethane thiosulfonate (MMTS). After discarding excess MMTS by precipitation with
acetone, protein samples were then reduced to thiols with 50 mM sodium ascorbate and biotinylated
with 33 µL reducing buffer (4 mM Biotin-HPDP, 1% SDS in standard buffer). After, the biotinylated
proteins were drawn out by neutravidin agarose-beads, eluted by SDS sample buffer at 95 ◦C for 5 min,
and detected by inmmunoblotting by specific ERK1/2 antibodies.
2.8.2. Detection and Quantification of Nitrated Proteins and iNOS by SDS-PAGE Blotting
Equal amounts of protein fractions (40 µg/sample) were dissolved with SDS sample buffer, heated
at 100 ◦C for 5 min, resolved on 10% SDS-polyacrylamid gels, transferred onto PVDF membranes, and
immunoblotted with primary antibody anti-nitrotyrosine (diluted at 1:2000), and then with secondary
antibody (diluted at 1:5000). Signals were detected using WesternBright Sirius HRP system detection
(Advansta Inc., San Jose, CA, USA) and then band intensity was measured using Image J software
(Wisconsin, NIH, USA).
2.9. Data Analysis
Data were statistically analyzed using the SPSS software (SPSS, Chicago, IL, USA). Comparisons
were done by using the Mann–Whitney U-test or Student’s t-test. Results are expressed as mean ±
standard deviation (SD) and differences were considered significant when p < 0.05.
3. Results
3.1. Clinical and Anthropometric Characteristics
The anthropometric and clinical parameters of the participants evaluated in study groups are
shown in Table 1. Both groups did not show significant differences related to all, with the exception of
the maternal BMI variables, which reflected a significant increase in obese group.
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Table 1. Clinical and anthropometric characteristics in normal weight and obese pregnant women.
Characteristics Lean Group (n = 9) Obese Group (n = 8)
Delivery mode Caesarean section(No labor)
Caesarean section
(No labor)
Maternal age (years) 33.1 ± 6.3 35.5 ± 6.4
Gestational age at delivery (weeks) 38.3 ± 1.0 38.3 ± 0.8
Pregravid Maternal BMI (kg/m2) 22.5 ± 1.3 35.5 ± 6.4 *
Maternal BMI at delivery (kg/m2) 28.1 ± 2.5 37.3 ± 5.7 *
Birthweight (g) 3182 ± 214 3170 ± 336
F/M sex ratio 5/4 5/3
Placental weight (g) 603 ± 75 604 ± 54
Data are given as mean ± standard deviation (SD). * p-value < 0.05 when compared to lean group by Mann–Whitney
U-test. BMI: body mass index; F/M: females/males.
3.2. Assesesment of Placental Antioxidant Defense Markers
Endogenous defense against an abundance of pro-oxidant agents involves an overall action
of antioxidant enzymes in order to detoxify free radicals and thus avoid possible tissue damage.
Regarding the main antioxidant enzymes, SOD 1 catalyzes the conversion of the O2•− radical to
H2O2, and then, cytosolic catalase transforms H2O2 to water. In placenta, there are two SOD isoforms,
copper-Zinc-containing SOD1 (Cu/Zn-SOD) at the villous stroma, and manganese-containing SOD2
(MnSOD) at the villous endothelium, both acting as the first line of antioxidant defense. The expression
of Cu/Zn-SOD and catalase is constitutive, although it may be stimulated by pro-oxidants, including
NO. In placental homogenates, SOD and catalase protein levels were found to be increased by Western
blotting in obese women (Figure 1). Converserely, their activities were found diminished in the obese
group, along with total antioxidant capacity (Figure 2).
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Figure 1. Total concentration of endogenous enzymatic antioxidants (catalase and Cooper/Zinc
SOD1) in full-term placentas from normal weight (lean; n = 9) and obese (OB; n = 8) women. These
antioxidant markers were assessed in placental protein extracts by Western blot analysis, as described
in the “Material and Methods” Section. Top: the y-axis represents the ratio of total antioxidant versus
β-actin in arbitrary units. Bottom: a representative picture of all Western blots is shown. Results were
reported as means ± SD. * p < 0.05 relative to the lean group.
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Figure 2. Endogenous antioxidant activity in full-term placentas from normal weight (lean, n = 9)
and obese (OB, n = 8) pregnancies. (a) SOD activity pattern was obtained by native SDS-PAGE on
10% (w/v) polyacrylamide gels, and then stained by the photochemical nitroblue tetrazolium method.
For each sample, 40 µg of protein was loaded per lane. A representative picture of all analyses
of the isoenzymatic SOD activity is shown. (b) Catalase activity and (c) TAC were quantified by
spectrophotometric analysis, as described in the “Material and Methods” Section. Results were reported
as mean ± SD of enzymatic activity. * p < 0.05 relative to the lean group. Cu/Zn SOD: Copper/Zinc
Superoxide dismutase; SDS-PAGE: sodium dodecyl sulfate-polyacrylamide gel electrophoresis; TAC:
total antioxidant capacity.
3.3. Ass sesment of Placental Oxida ive Damage Markers
We further investigated two universal parameters related to the generation of key pro-oxidants
involved in the development of OS. Pro-oxidant agents attack cell membrane phospholipids and react
with polyunsaturated fatty acids to form lipid peroxides, an indicator of lipid oxidation. In obese
placentas, a non-significant trend towards decreased TBARS levels as a lipid peroxidation biomarker
was found (~25%, p-value = 0.10) (Figure 3a). On the other hand, protein carbonyls formation,
a hallmark of protein oxidation specially caused by O2•−, showed a significant decrease in placentas
from obese pregnancies (~30%, p-value = 0.045).
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3.4. Nitrosative Stress Markers
iNOS expression, a marker of inflammation and NO production, showed a significant increment
in expression levels in human placenta from the obese egnant compared to lean group (Figure 4a),
demonstrati g that inducible isoform of NOS i activated in villous tissue under pathological
conditions, such as maternal obesity. On the other h nd, formation on S-Nitrosothiol groups, termed as
S-Nitrosylation, has been widely recognized as a main actor in cellular signaling pathways, especially
associated to activation of proteins of cell survival. Thus, the ERK1/2 pathway is highly regulated by
action of NO through mechanisms related to PTMs in various pathophysiological conditions. We used
the Biotin-Switch assay in order to measure the levels of placental ERK1/2-SNO in both groups, and
a significant decrease was found in placental tissue from pregnant women with obesity (Figure 4b). An
increased NO production, with reduced S-Nitrosylation, suggests alternative NO-mediated regulation
mechanisms, such as protein nitration. To assess this, we determined the nitration protein profile in
full-term placentas of both normoweight and obese pregnancies. Equal amounts of placental protein
extracts were detected via immunoblotting with anti-nitrotyrosine antibody. As shown in Figure 4c,
total NO2-proteins levels increased significantly in obese placentas compared to those in the lean group.
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Figure 4. NO-induced nitrosative stress markers in placental samples from normal weight (lean, n
= 9) and obese (OB, n = 8) pregnancies. (a) iNOS expression levels. This enzyme was assessed in
placental protein extracts by Western blot analysis, as described in the “Material and Methods” Section.
(b) Detection and quantification of ERK nitrosylated (SNO-ERK1,2) levels. The placental extracts were
processed and subjected to the Biotin-Switch method. The biotin-labeled SNO proteins were further
subjected to neutravidin capture, separated by using 10% by SDS-PAGE, and immunoblotted with
an anti-ERK antibody. Total ERK were represented as total protein (input). (c) Detection of nitrated
proteins by immunoblot analysis using antinitrotyrosine antibodies. In each lane, all nitrated proteins
were counted in order to quantify the total nitration protein level for each placental sample. Molecular
weight markers (M) and sizes (kDa) are shown, and also possible targets of nitrated proteins (arrows)
are indicated. In all cases: top represents the mean densitometry expressed in arbitrary units and
bottom shows a representative picture of all Western blots. The results were expressed as means ± SD.
* p < 0.05 relative to the lean group or input. iNOS: inducible nitric oxide synthase.
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4. Discussion
The incidence of obesity before pregnancy is quickly increasing worldwide in the 21st Century and
is currently considered a chronic inflammatory condition that may negatively affect both mother and
fetus, and their offspring [38,39]. The placenta appears to play an essential role during gestation given
its intermediate situation and regulatory functions. Thus, this organ may respond to perturbations in
the intrauterine environment throughout pregnancy, even at early stages of pregnancy, with negative
consequences for the development of the fetus [40]. In this sense, an obesogenic millieu can lead to
overproduction of ROS and RNS, which may ultimately lead to changes in the normal structure and
function of the placenta. Therefore, a right balance between pro-oxidants agents (H2O2, O2•−, or NO),
antioxidant systems (catalase, SOD), as well as pro-oxidative enzymes (NADPH and xanthine oxidase or
nitric oxide synthases) seems crucial in maintaining placental homeostatic capacity to initiate a normal
adaptive response during pregnancy [41]. Our findings highlight the existence of an imbalance of
the antioxidant/ROS/RNS system in human placenta from pregnancies with pregravid maternal obesity
without associated metabolic complications during gestation, which is characterized by a failure of
the antioxidant response, along with a decrease in oxidative damage and an enhanced NO-induced
nitrosative stress, predominantly by abundance of nitrotyrosine groups via protein nitration.
At the beginning of pregnancy with pregravid obesity, a chronic inflammation may activate a set
of mechanisms that ultimately form an adverse intrauterine inflammatory environment throughout
pregnancy. In this sense, the accumulation of a heterogeneous population of macrophages and
pro-inflammatory mediators have been found in placenta from obese pregnancies [42]. On the other
hand, placental mitochondrial dysfunction has been observed with increased maternal adiposity, along
with exacerbated ROS production [17]. The main physiological source of ROS in placenta is the NADPH
oxidase (NOX) family, especially NOX1 and NOX5 isoforms, identified in syncytiotrophoblast and
vascular endothelium [43]. Other enzyme systems such as xanthine oxidase and the mitochondrial
respiratory chain are also involved. Hernandez et al. demonstrated that both NOX isoforms are
the most relevant source of placental superoxide anion, and also, the NOX activity is higher in the first
trimester, along with increased antioxidant activities (e.g., SOD, catalase, or glutathione peroxidase) [44].
Moreover, an adipogenic and inflammatory state found in certain physiological pregnancies have been
related to changes both in the pro-oxidant and antioxidant defense levels [45,46].
Although OS has been observed in the normal development of the placenta, it clearly seems to
be involved in the pathophysiology of pregnancy-associated complications such as PE and GDM [19,
20,47,48]. However, studies on OS in maternal obesity are scarce and controversial [17,21,22]. In
this sense, our approach has been the assessement of placentas from obese women without any
medical complications or metabolic factors, including GDM or insulin resistance. Furthermore, all
pregnant women were eligible regarding mode of delivery (elective Caesarean section) in order to avoid
the potential impact of labor on placental OS. Also highlighted is the fact the all patients were elegible
as metabolically healthy pregnancies based on three biochemical parameters such as plasma glucose,
cholestherol and tryglicerides levels, which exhibited normal physiological levels in pregnancy.
In the present study, we first observed a significant decrease in the activity of catalase and SOD
antioxidant enzymes in full-term placenta, in spite of an increase in its concentrations, as well as
a reduction in total antioxidant capacity (Figures 1 and 2). In parallel, our results show a strong trend
of decreased oxidative damage characterized by a decrease in the levels of universal OS markers
such as TBARS and carbonyl groups (Figure 3). This overall data reveals the existence of a placental
inactivation of antioxidant system response, which would eventually lead to elevated OS in obese
women’s pregnancies. However, this conflicting condition is not accompained by a subsequent increase
of oxidative damage, including those involved in lipid peroxidation and protein oxidation. This was
partially in agreement with other authors who showed lower carbonyl groups formation in placenta
of pregnant women with overweight, but not in obese pregnant women, in addition to an unaltered
SOD activity among groups [22]. In contrast, Malti et al. found OS-induced oxidative damage in
placenta of obese mothers, including showing a high antioxidant activity [21]. In relation to other
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pregnancy-associated disorders, a reduced enzymatic capacity and increased oxidation has been
demonstrated in placenta tissue from preeclamptic women, contributing to the pathogenesis of this
gestational disorder [49]. On the other hand, increased oxidative stress in late gestation was observed
in several pregnancy-related disorders in association with increased trophoblast apoptosis and altered
placental vascular endothelium [50]. Meanwhile, other promising studies have revealed the presence
of possible alterations in ROS/SOD ratio based on upregulation of the SOD along with the activation of
the superoxide anion degradation pathway at the vascular level in cardiovascular diseases [51].
NO is an essential pleiotropic agent that, under normal physiological conditions, is involved in
the regulation of different biological processes, including cell respiration, apoptosis, and proliferation
of cells, vascular tone, or gene expression. In human reproductive physiology, NO plays an
important role in expression-dependent events of certain signaling molecules (e.g., vascular endothelial
growth factor-VEGF), including angiogenesis or vasculogenesis [52]. Thus, an appropriate placental
vascularization is necessary to ensure a correct fetal development throughout the gestation. During
gestation, NO is synthesized by various NOS isoforms, including endothelial (eNOS) and inducible
(iNOS) NO synthases. iNOS expression has been clearly demonstrated in human placenta, so it
might play an important role in placental pathophysiology [53]. In this sense, an excessive NO
production by the inducible iNOS enzyme has been widely implicated in the pathogenesis of various
neurodegenerative, inflammatory, or metabolic diseases [24,54]. Thus, some authors suggest that
maternal diabetes is related to an increased expression of the iNOS enzyme and consequently,
NO-induced nitrosative stress and cell death [55,56]. Meanwhile, an increase in the production of NO
has been reported in pregnancy in which the placenta is the main target of these perturbations [57]. Thus,
S-Nitrosylation is a well-known post-translational regulation mechanism by which NO can directly
modulate protein function, resulting in altered protein activity and adverse biological consequences [58].
We have previously found an increase of NO-related nitrosative stress by detection of SNO proteins
involved in key cellular physiological events, such as cell death, the antioxidant system, and cell
signalling [25]. In the present study, we found increased iNOS expression in full-term placental tissue
from the obese mothers (Figure 4a), which is in line with other reports [59,60]. On the other hand,
cell signaling-related proteins have been described as potential targets of S-nitrosylation, including
ERK1/2 [24], which may be essential in regulation of placental processes such as cell replication and
trophoblast differentiation. In addition, several studies have highlighted a major role of S-nitrosylation
ERK1/2 in various pathophysiological models, which indicates that protein S-Nitrosylation could be
crucial for progression of knowledge of NO biology in pregnancy [61]. In this sense, our data show
a significant decrease in nitrosothiol group levels in ERK1/2 protein (Figure 4b), thereby reducing
S-Nitrosylation in placentas from obese mothers and, consequently, NO bioavailabilty in other relevant
processes. In addition, we measured the concentration of phosphorylated ERK1/2 (active form),
showing a notably increased activation (data not shown), which seems to indicate that a compensatory
regulatory mechanism may be occurring oriented towards the activation of processes related to cell
survival rather than cell death, possibly in order to protect the cell function.
Protein nitration, another NO-induced PTM, is extensively present in certain pathological states
and systems [27,62,63]. An excess of free radicals can result in the generation of ONOO-, a reactive
intermediate of the interaction between the NO and O2- anion. This potent pro-oxidant agent has
a relatively high half-life and and it is able to induce a damage in membrane lipids or modify
proteins by PTMs, particularly at the tyrosine residues, leading to the formation of nitrotyrosine
groups [24]. Formation of these nitrotyrosine residues has been widely documented as a hallmark
of nitrative stress [64]. During gestation, nitrotyrosine generation in placenta has been identified
in complicated pregnancies, especially PE and GDM, and recognized as primarily responsible for
the increase in maternal and perinatal mortality [28,65]. In this sense, our results show the existence
of higher levels of protein nitration in placenta tissue of uncomplicated obese mothers, possibly
by modification of placental proteins linked to several biological pathways (Figure 4c). An altered
placental nitro-proteome, characterized by the accumulation of nitrotyrosine residues in key proteins,
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could strongly participate in the placental pathophysiology in pregnancy-related disorders, including
maternal obesity [66,67]. Other previous works support this hypothesis of nitrotyrosine action in
protein and placental villous (especially in syncytiothrophoblast), or that vascular endothelium may
ultimately alter proteins and placental functions [28,29,68–70] and contribute to the occurence of
long-term metabolic and cardiovascular diseases, both in the mother and in offspring.
5. Conclusions
A redox imbalance occurs when the antioxidant response is overflowed, consequently leading
to the activation of alternative pathways that, under normal conditions, remain inactive. In this
context, we first suggest that the protein nitration may be playing a positive regulatory role, which, if
exceeded, could lead to damage in human placenta. Moreover, we secondly propose that an adaptive
mechanism of the placenta could be occurring in a healthy maternal obesogenic context. Thus, a failure
in the balance of antioxidant/ROR/RNS unit could result in an increased NO-induced nitrosative stress,
accompanied by an inactivation of antioxidant systems and a reduction of oxidative damage, thus
redirecting the superoxide radicals accumulated along with NO to the formation of peroxynitrite,
and ultimately to an increase in protein nitration (Figure 5). Therefore, it seems that NO-induced
nitrosative stress preceeds oxidative stress in pregnancies from metabolically healthy maternal obesity.
Further studies are needed to reveal the possible targets of NO and peroxynitrite action on key proteins
in pregnancy-related disorders such as maternal obesity, in order to analyze the possible effects in
the placenta function and, consequently, in fetal development and programming.
Antioxidants 2020, 9, 794 13 of 17
Antioxidants 2020, 9, x 13 of 17 
 
Figure 5. Proposed model of formation of a placental antioxidant/ROS/RNS unit imbalance in 
pregnancy with metabollicaly healthy maternal obesity. ROS: reactive oxygen species; RNS: reactive 
nitrogen species; TG: Triglycerides; NO: nitric oxide; iNOS: inducible nitric oxide synthase; SOD: 
superoxide dismutase; CAT: catalase; O2●−: superoxide anion; H2O2: hydrogen peroxide; ONOO●−: 
peroxynitrite; LPO: lipoperoxides; C=O: carbonyl groups; HyperCHO: hypercholesterolemia; 
HyperTG: hypertriglyceridemia; HyperGLY: hyperglycemia; 㐅 symbol: absence of. 
Author Contributions: F.V. and M.R.M. designed the experimental approach and directed the project. F.V. 
wrote, edited, and revised the manuscript and performed the statistical analysis. C.S.-R. performed the 
experimental work. F.B. recruited and evaluated participants and was responsible for their clinical follow-up. 
A.G.-D. gave technical support. A.M.L.-S., F.B., M.R.M., and F.V. interpreted and discussed the results, making 
critical contributions. All authors have read and agreed to the published version of the manuscript. 
Funding: This research received no external funding. 
Figure 5. r l f for ation of a placental antioxidant/ROS/RNS unit imbalance in
pregnancy with metabol ic l aternal obesity. ROS: reactive oxygen sp cies; RNS: reactive
nitrogen species; T : rigl ; : nitric oxide; iNOS: inducible n tric oxide synthase; SOD:
superoxide dismutase; CAT: catalase; O2• : superoxide anion; H2O2: hydrogen peroxide; ONOO•−:
peroxynitrite; LPO: lipoperoxides; C=O: carbonyl groups; HyperCHO: hypercholesterolemia; HyperTG:
hypertriglyceridemia; HyperGLY: hyperglycemia;
Antioxidants 2020, 9, x  13  of  17 
 
Figure  5.  Propos d model  of  formation  of  a  placental  antioxid nt/ROS/RNS  unit  imbala ce  in 
pregnancy with metaboll caly healthy mat rnal obesity. ROS: reactive oxygen species; RNS: reactive 
nitrogen  spec es; TG: Triglycerides; NO: nitric oxide;  iNOS:  inducible  itric oxide  synthase; SOD: 
superoxide dismutas ; CAT: c talase; O2●−:  superoxide anion; H2O2: hydrogen pe xid ; ONOO●−: 
peroxynitrit ;  LPO:  lipoperoxides;  C=O:  carbonyl  groups;  HyperCHO:  hypercholesterolemia; 
HyperTG: hypertriglyceridemia; HyperGLY: hyperglycemia; 㐅  symbol: absence of. 
Author Contributions: F.V.  and M.R.M. designed  the  experimental  approach  and directed  the project. F.V. 






Author Contributions: F.V. and R.M.M. designed the experiment l approach and directed the project. F.V. wrote,
edited, and revised the manuscript and p rform the statistical analysis. C.S.-R. p r med the experimental work.
F.B. recruited and evaluated participants and was responsible for th ir clinic l follow-up. A.G.-D. gave technical
support. A.M.L.-S., F.B., R.M.M., and F.V. interpreted and discussed the results, making critical contributions. All
authors have read and agreed to the published version of the manuscript.
Funding: This r search r ceived no external funding.
Antioxidants 2020, 9, 794 14 of 17
Conflicts of Interest: The authors declare that there are no conflicts of interest that would prejudice the impartiality
of this scientific work.
References
1. Swinburn, B.A.; Sacks, G.; Hall, K.D.; McPherson, K.; Finegood, D.T.; Moodie, M.L.; Gortmaker, S.L.
The global obesity pandemic: Shaped by global drivers and local environments. Lancet 2011, 378, 804–814.
[CrossRef]
2. Arora, R.; Arora, D.; Patumanond, J. Adverse pregnancy outcomes in women with high pre-pregnancy body
mass index. Open J. Obstet. Gynecol. 2013, 3, 285–291. [CrossRef]
3. Leddy, M.A.; Power, M.L.; Schulkin, J. The impact of maternal obesity on maternal and fetal health. Rev.
Obstet. Gynecol. 2008, 1, 170–178. [PubMed]
4. Lisonkova, S.; Muraca, G.M.; Potts, J.; Liauw, J.; Chan, W.-S.; Skoll, A.; Lim, K.I. Association Between
Prepregnancy Body Mass Index and Severe Maternal Morbidity. JAMA 2017, 318, 1777. [CrossRef] [PubMed]
5. Sun, Y.; Shen, Z.; Zhan, Y.; Wang, Y.; Ma, S.; Zhang, S.; Liu, J.; Wu, S.; Feng, Y.; Chen, Y.; et al. Effects of
pre-pregnancy body mass index and gestational weight gain on maternal and infant complications. BMC
Pregnancy Childbirth 2020, 20, 390. [CrossRef] [PubMed]
6. Yogev, Y.; Catalano, P.M. Pregnancy and Obesity. Obstet. Gynecol. Clin. N. Am. 2009, 36, 285–300. [CrossRef]
[PubMed]
7. Catalano, P.M.; Presley, L.; Minium, J.; Hauguel-de Mouzon, S. Fetuses of Obese Mothers Develop Insulin
Resistance in Utero. Diabetes Care 2009, 32, 1076–1080. [CrossRef]
8. Rkhzay-Jaf, J.; O’Dowd, J.F.; Stocker, C.J. Maternal Obesity and the Fetal Origins of the Metabolic Syndrome.
Curr. Cardiovasc Risk Rep. 2012, 6, 487–495. [CrossRef]
9. Laker, R.C.; Wlodek, M.E.; Connelly, J.J.; Yan, Z. Epigenetic origins of metabolic disease: The impact of
the maternal condition to the offspring epigenome and later health consequences. Food Sci. Hum. Wellness
2013, 2, 1–11. [CrossRef]
10. Fernández-Sánchez, A.; Madrigal-Santillán, E.; Bautista, M.; Esquivel-Soto, J.; Morales-González, Á.;
Esquivel-Chirino, C.; Durante-Montiel, I.; Sánchez-Rivera, G.; Valadez-Vega, C.; Morales-González, J.A.
Inflammation, Oxidative Stress, and Obesity. Int. J. Mol. Sci. 2011, 12, 3117–3132. [CrossRef]
11. Bugatto, F.; Fernández-Deudero, Á.; Bailén, Á.; Fernández-Macías, R.; Hervías-Vivancos, B.; Bartha, J.L.
Second-Trimester Amniotic Fluid Proinflammatory Cytokine Levels in Normal and Overweight Women.
Obstet. Gynecol. 2010, 115, 127–133. [CrossRef] [PubMed]
12. Howell, K.R.; Powell, T.L. Effects of maternal obesity on placental function and fetal development. Reproduction
2017, 153, R97–R108. [CrossRef] [PubMed]
13. Kelly, A.C.; Powell, T.L.; Jansson, T. Placental function in maternal obesity. Clin. Sci. 2020, 134, 961–984.
[CrossRef] [PubMed]
14. Myatt, L.; Maloyan, A. Obesity and Placental Function. Semin. Reprod. Med. 2016, 34, 042–049. [CrossRef]
15. Burton, G.J.; Jauniaux, E. Oxidative stress. Best Pract. Res. Clin. Obstet. Gynaecol. 2011, 25, 287–299.
[CrossRef]
16. Myatt, L.; Cui, X. Oxidative stress in the placenta. Histochem. Cell Biol. 2004, 122, 369–382. [CrossRef]
17. Mele, J.; Muralimanoharan, S.; Maloyan, A.; Myatt, L. Impaired mitochondrial function in human placenta
with increased maternal adiposity. Am. J. Physiol. Endocrinol. Metab. 2014, 307, E419–E425. [CrossRef]
18. Mannaerts, D.; Faes, E.; Cos, P.; Briedé, J.J.; Gyselaers, W.; Cornette, J.; Gorbanev, Y.; Bogaerts, A.;
Spaanderman, M.; Van Craenenbroeck, E.; et al. Oxidative stress in healthy pregnancy and preeclampsia is
linked to chronic inflammation, iron status and vascular function. PLoS ONE 2018, 13, e0202919. [CrossRef]
19. Coughlan, M.T.; Vervaart, P.P.; Permezel, M.; Georgiou, H.M.; Rice, G.E. Altered Placental Oxidative Stress
Status in Gestational Diabetes Mellitus. Placenta 2004, 25, 78–84. [CrossRef]
20. Lappas, M.; Hiden, U.; Desoye, G.; Froehlich, J.; Mouzon, S.H.; Jawerbaum, A. The Role of Oxidative Stress in
the Pathophysiology of Gestational Diabetes Mellitus. Antioxid. Redox Signal. 2011, 15, 3061–3100. [CrossRef]
21. Malti, N.; Merzouk, H.; Merzouk, S.A.; Loukidi, B.; Karaouzene, N.; Malti, A.; Narce, M. Oxidative stress
and maternal obesity: Feto-placental unit interaction. Placenta 2014, 35, 411–416. [CrossRef] [PubMed]
Antioxidants 2020, 9, 794 15 of 17
22. Roberts, V.H.J.; Smith, J.; McLea, S.A.; Heizer, A.B.; Richardson, J.L.; Myatt, L. Effect of Increasing Maternal
Body Mass Index on Oxidative and Nitrative Stress in The Human Placenta. Placenta 2009, 30, 169–175.
[CrossRef]
23. Alanis, M.C.; Steadman, E.M. Maternal Obesity and Placental Oxidative Stress in the First Trimester. J. Obes.
Weight Loss Ther. 2012, 2. [CrossRef]
24. Pacher, P.; Beckman, J.S.; Liaudet, L. Nitric Oxide and Peroxynitrite in Health and Disease. Physiol. Rev. 2007,
87, 315–424. [CrossRef] [PubMed]
25. Visiedo, F.; Santos-Rosendo, C.; Mateos-Bernal, R.M.; Gil-Sánchez, M.; Bugatto, F.; Aguilar-Diosdado, M.;
Segundo, C.; López-Tinoco, C. Characterization of NO-Induced Nitrosative Status in Human Placenta
from Pregnant Women with Gestational Diabetes Mellitus. Oxidative Med. Cell. Longev. 2017, 2017, 1–10.
[CrossRef] [PubMed]
26. Zhang, H.; Wang, Y.; Chen, D. Analysis of Nitroso-Proteomes in Normotensive and Severe Preeclamptic
Human Placentas1. Biol. Reprod. 2011, 84, 966–975. [CrossRef]
27. Webster, R.P.; Roberts, V.H.J.; Myatt, L. Protein Nitration in Placenta—Functional Significance. Placenta 2008,
29, 985–994. [CrossRef]
28. Lyall, F.; Gibson, J.L.; Greer, I.A.; Brockman, D.E.; Eis, A.L.; Myatt, L. Increased Nitrotyrosine in the Diabetic
Placenta: Evidence for oxidative stress. Diabetes Care 1998, 21, 1753–1758. [CrossRef]
29. Myatt, L.; Rosenfield, R.B.; Eis, A.L.W.; Brockman, D.E.; Greer, I.; Lyall, F. Nitrotyrosine Residues in Placenta:
Evidence of Peroxynitrite Formation and Action. Hypertension 1996, 28, 488–493. [CrossRef]
30. Rey-López, J.P.; de Rezende, L.F.; Pastor-Valero, M.; Tess, B.H. The prevalence of metabolically healthy
obesity: A systematic review and critical evaluation of the definitions used: Prevalence of metabolically
healthy obesity. Obes. Rev. 2014, 15, 781–790. [CrossRef]
31. National Diabetes Data Group Classification and Diagnosis of Diabetes Mellitus and Other Categories of
Glucose Intolerance. Diabetes 1979, 28, 1039–1057. [CrossRef] [PubMed]
32. Buege, J.A.; Aust, S.D. Microsomal lipid peroxidation. In Methods in Enzymology; Elsevier: Amsterdam,
The Netherlands, 1978; Volume 52, pp. 302–310. ISBN 978-0-12-181952-1.
33. Levine, R.L.; Garland, D.; Oliver, C.N.; Amici, A.; Climent, I.; Lenz, A.G.; Ahn, B.W.; Shaltiel, S.; Stadtman, E.R.
Determination of carbonyl content in oxidatively modified proteins. Meth. Enzym. 1990, 186, 464–478.
[CrossRef] [PubMed]
34. Beauchamp, C.; Fridovich, I. Superoxide dismutase: Improved assays and an assay applicable to acrylamide
gels. Anal. Biochem. 1971, 44, 276–287. [CrossRef]
35. Aebi, H. Catalase in vitro. In Methods in Enzymology; Elsevier: Amsterdam, The Netherlands, 1984; Volume
105, pp. 121–126. ISBN 978-0-12-182005-3.
36. Erel, O. A novel automated method to measure total antioxidant response against potent free radical reactions.
Clin. Biochem. 2004, 37, 112–119. [CrossRef] [PubMed]
37. Jaffrey, S.R.; Snyder, S.H. The Biotin Switch Method for the Detection of S-Nitrosylated Proteins. Sci. Signal.
2001, 2001, pl1. [CrossRef]
38. Deruelle, P. Obésité et grossesse. Gynécologie Obs. Fertil. 2011, 39, 100–105. [CrossRef]
39. Aviram, A.; Hod, M.; Yogev, Y. Maternal obesity: Implications for pregnancy outcome and long-term risks-a
link to maternal nutrition. Int. J. Gynecol. Obstet. 2011, 115, S6–S10. [CrossRef]
40. Desoye, G. The Human Placenta in Diabetes and Obesity: Friend or Foe? The 2017 Norbert Freinkel Award
Lecture. Diabetes Care 2018, 41, 1362–1369. [CrossRef]
41. Wu, F.; Tian, F.-J.; Lin, Y.; Xu, W.-M. Oxidative Stress: Placenta Function and Dysfunction. Am. J. Reprod.
Immunol. 2016, 76, 258–271. [CrossRef]
42. Challier, J.C.; Basu, S.; Bintein, T.; Minium, J.; Hotmire, K.; Catalano, P.M.; Hauguel-de Mouzon, S. Obesity
in Pregnancy Stimulates Macrophage Accumulation and Inflammation in the Placenta. Placenta 2008, 29,
274–281. [CrossRef]
43. Cui, X.-L.; Brockman, D.; Campos, B.; Myatt, L. Expression of NADPH Oxidase Isoform 1 (Nox1) in Human
Placenta: Involvement in Preeclampsia. Placenta 2006, 27, 422–431. [CrossRef] [PubMed]
44. Hernandez, I.; Fournier, T.; Chissey, A.; Therond, P.; Slama, A.; Beaudeux, J.-L.; Zerrad-Saadi, A. NADPH
oxidase is the major source of placental superoxide in early pregnancy: Association with MAPK pathway
activation. Sci. Rep. 2019, 9, 13962. [CrossRef]
Antioxidants 2020, 9, 794 16 of 17
45. Toescu, V.; Nuttall, S.L.; Martin, U.; Kendall, M.J.; Dunne, F. Oxidative stress and normal pregnancy:
Oxidative stress and normal pregnancy. Clin. Endocrinol. 2002, 57, 609–613. [CrossRef]
46. Leal, C.A.M.; Schetinger, M.R.C.; Leal, D.B.R.; Morsch, V.M.; da Silva, A.S.; Rezer, J.F.P.; de Bairros, A.V.;
Jaques, J.A. dos S. Oxidative stress and antioxidant defenses in pregnant women. Redox Rep. 2011, 16,
230–236. [CrossRef] [PubMed]
47. Madazli, R.; Benian, A.; Aydin, S.; Uzun, H.; Tolun, N. The plasma and placental levels of malondialdehyde,
glutathione and superoxide dismutase in pre-eclampsia. J. Obstet. Gynaecol. 2002, 22, 477–480. [CrossRef]
[PubMed]
48. Biri, A.; Onan, A.; Devrim, E.; Babacan, F.; Kavutcu, M.; Durak, I. Oxidant status in maternal and cord plasma
and placental tissue in gestational diabetes. Placenta 2006, 27, 327–332. [CrossRef] [PubMed]
49. Vanderlelie, J.; Venardos, K.; Clifton, V.L.; Gude, N.M.; Clarke, F.M.; Perkins, A.V. Increased biological
oxidation and reduced anti-oxidant enzyme activity in pre-eclamptic placentae. Placenta 2005, 26, 53–58.
[CrossRef]
50. Alcala, M.; Gutierrez-Vega, S.; Castro, E.; Guzman-Gutiérrez, E.; Ramos-Álvarez, M.P.; Viana, M. Antioxidants
and Oxidative Stress: Focus in Obese Pregnancies. Front. Physiol. 2018, 9, 1569. [CrossRef]
51. Wongsurawat, T.; Woo, C.C.; Giannakakis, A.; Lin, X.Y.; Cheow, E.S.H.; Lee, C.N.; Richards, M.; Sze, S.K.;
Nookaew, I.; Kuznetsov, V.A.; et al. Distinctive molecular signature and activated signaling pathways
in aortic smooth muscle cells of patients with myocardial infarction. Atherosclerosis 2018, 271, 237–244.
[CrossRef]
52. Krause, B.J.; Hanson, M.A.; Casanello, P. Role of nitric oxide in placental vascular development and function.
Placenta 2011, 32, 797–805. [CrossRef]
53. Schönfelder, G.; John, M.; Hopp, H.; Fuhr, N.; Van Der Giet, M.; Paul, M. Expression of inducible nitric oxide
synthase in placenta of women with gestational diabetes. FASEB J. 1996, 10, 777–784. [CrossRef] [PubMed]
54. Sharma, J.N.; Al-Omran, A.; Parvathy, S.S. Role of nitric oxide in inflammatory diseases. Inflammopharmacology
2007, 15, 252–259. [CrossRef] [PubMed]
55. Yang, P.; Cao, Y.; Li, H. Hyperglycemia induces inducible nitric oxide synthase gene expression and
consequent nitrosative stress via c-Jun N-terminal kinase activation. Am. J. Obstet. Gynecol. 2010, 203,
185.e5–185.e11. [CrossRef] [PubMed]
56. Weng, H.; Li, X.; Reece, E.A.; Yang, P. SOD1 suppresses maternal hyperglycemia-increased iNOS expression
and consequent nitrosative stress in diabetic embryopathy. Am. J. Obstet. Gynecol. 2012, 206, 448.e1–448.e7.
[CrossRef]
57. Zullino, S.; Buzzella, F.; Simoncini, T. Nitric oxide and the biology of pregnancy. Vasc. Pharmacol. 2018, 110,
71–74. [CrossRef]
58. Foster, M.W.; McMahon, T.J.; Stamler, J.S. S-nitrosylation in health and disease. Trends Mol. Med. 2003, 9,
160–168. [CrossRef]
59. Page, A.J. NO regulation of gut-brain signalling in obesity. J. Physiol. 2019, 597, 1425–1426. [CrossRef]
60. Yu, Y.; Park, S.J.; Beyak, M.J. Inducible nitric oxide synthase-derived nitric oxide reduces vagal satiety
signalling in obese mice. J. Physiol. 2019, 597, 1487–1502. [CrossRef]
61. Feng, X.; Sun, T.; Bei, Y.; Ding, S.; Zheng, W.; Lu, Y.; Shen, P. S-nitrosylation of ERK inhibits ERK
phosphorylation and induces apoptosis. Sci. Rep. 2013, 3, 1814. [CrossRef]
62. Castegna, A.; Thongboonkerd, V.; Klein, J.B.; Lynn, B.; Markesbery, W.R.; Butterfield, D.A. Proteomic
identification of nitrated proteins in Alzheimer’s disease brain: Nitrated proteins in AD brain. J. Neurochem.
2003, 85, 1394–1401. [CrossRef]
63. Sabetkar, M.; Low, S.Y.; Naseem, K.M.; Bruckdorfer, K.R. The nitration of proteins in platelets: Significance
in platelet function 1,2 1This article is part of a series of reviews on “Reactive Nitrogen Species, Tyrosine
Nitration and Cell Signaling.” The full list of papers may be found on the homepage of the journal. 2Guest
Editor: Harry Ischiropoulos. Free Radic. Biol. Med. 2002, 33, 728–736. [CrossRef] [PubMed]
64. Radi, R. Protein Tyrosine Nitration: Biochemical Mechanisms and Structural Basis of Functional Effects. Acc.
Chem. Res. 2013, 46, 550–559. [CrossRef] [PubMed]
65. Bosco, C.; González, J.; Gutiérrez, R.; Parra-Cordero, M.; Barja, P.; Rodrigo, R. Oxidative damage to
pre-eclamptic placenta: Immunohistochemical expression of VEGF, nitrotyrosine residues and von Willebrand
factor. J. Matern. Fetal Neonatal Med. 2012, 25, 2339–2345. [CrossRef] [PubMed]
Antioxidants 2020, 9, 794 17 of 17
66. Jauniaux, E.; Burton, G.J. Le rôle du stress oxydant dans les pathologies placentaires de la grossesse. J.
Gynécologie Obs. Biol. Reprod. 2016, 45, 775–785. [CrossRef]
67. Salvolini, E.; Vignini, A.; Sabbatinelli, J.; Lucarini, G.; Pompei, V.; Sartini, D.; Cester, A.M.; Ciavattini, A.;
Mazzanti, L.; Emanuelli, M. Nitric oxide synthase and VEGF expression in full-term placentas of obese
women. Histochem. Cell Biol. 2019, 152, 415–422. [CrossRef] [PubMed]
68. White, V.; Capobianco, E.; Higa, R.; Martínez, N.; Sosa, M.; Pustovrh, M.C.; Jawerbaum, A. Increased nitration
and diminished activity of copper/zinc superoxide dismutase in placentas from diabetic rats. Free Radic. Res.
2010, 44, 1407–1415. [CrossRef] [PubMed]
69. Webster, R.P.; Brockman, D.; Myatt, L. Nitration of p38 MAPK in the placenta: Association of nitration with
reduced catalytic activity of p38 MAPK in pre-eclampsia. MHR Basic Sci. Reprod. Med. 2006, 12, 677–685.
[CrossRef]
70. Schoots, M.H.; Gordijn, S.J.; Scherjon, S.A.; van Goor, H.; Hillebrands, J.-L. Oxidative stress in placental
pathology. Placenta 2018, 69, 153–161. [CrossRef]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
